Oncology Drug Discovery Applications Using the FMAT™ 8100 HTS System
Jennifer Y. Lee, Sheri J. Miraglia, Xiongwei Yan, Elana E. Swartzman, Susan Cornell-Kennon, Julia Mellentin-Michelotti, Charles W. Bruseo, Dennis S. France · SLAS DISCOVERY · 2003
High-throughput screening (HTS) for potential anticancer agents requires a broad portfolio of assay platforms that may include kinase enzyme assays, protein-protein binding assays, and functional cell-based apoptosis assays. The authors have explored the use of fluorometric microvolume assay technology (the FMAT 8100 HTS System) in three distinct homogeneous HTS assays: (1). a Src tyrosine kinase enzyme assay, (2). a Grb2-SH2 protein-peptide interaction assay, and (3). an annexin V binding apoptosis assay. Data obtained from all three assays suggest that the FMAT system should facilitate the implementation of homogeneous assays for a wide variety of molecular targeted and cell-based screens.